omatic lesions. Many
CAS studies have been in the form of “high-risk” registries.185,211-216 In 2004, the SAPPHIRE trial, which
included “high-risk” patients (70% of whom were
asymptomatic) demonstrated that stenting with cerebral protection devices was not inferior to CEA.201 The
primary end point of the study was 30-day cumulative
incidence